Adjuvants are critical components in vaccines, added to enhance the immune response, making vaccines more effective with smaller antigen doses. By stimulating the innate immune system, adjuvants attract immune cells to the injection site and promote a more robust adaptive immune response. Common adjuvants include aluminum salts, which are widely used, as well as newer formulations like MF59, an oil-in-water emulsion. Adjuvants allow vaccines to achieve protective immunity more efficiently, especially in populations with weaker immune responses, such as the elderly or immunocompromised individuals. This enhancement not only increases vaccine efficacy but also supports the development of vaccines against complex pathogens. As adjuvant research advances, new formulations could potentially make vaccines more accessible and effective worldwide, especially in settings with limited healthcare resources.
Duccio Medini
BioForge, United States
Jocelyn Jakubik
Apex Pathogen Solutions, United States
Sergey V Suchkov
N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Rosane Cuber Guimaraes
Bio-Manguinhos/ Fiocruz, Brazil
Aghapy Yermans Yakoup
Zewail City of Science and Technology, Egypt
Rosane Cuber Guimaraes
Bio-Manguinhos/ Fiocruz, Brazil
Zhujun Ao
University of Manitoba, Canada
K R Aneja
Kurukshetra University, India
Jocelyn Jakubik
Apex Pathogen Solutions, United States
Huanhuan Li
Queen’s University Belfast, United KingdomSubmit your abstract Today
Title : A universal AI design framework and brokerage platform for democratised manufacturing of mRNA therapeutics
Duccio Medini, BioForge, United States
Title : Personalized and Precision Medicine (PPM) via biodesign-driven translational applications and upgraded business modeling to secure the human biosafety: The next-step vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Development of VSV-vector based vaccine against H5N1 avian influenza by targeting both H5N1 hemagglutinin and matrix protein 2
Zhujun Ao, University of Manitoba, Canada
Title : A novel responsive microneedle platform for reliable drug and vaccine delivery
Huanhuan Li, Queen’s University Belfast, United Kingdom
Title : Emerging nanovaccine strategies for enhanced immune targeting and vaccine performance
Aysel Sadayli, V.Y. Axundov Scientific-Research Institute of Medical Prophylaxis, Azerbaijan
Title : The promise of nanotechnology in Personalized & Precision Medicine: Nano-driven precision vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Reaching zero-dose children through adaptive immunization strategies in security-compromised areas of Zamfara State, Nigeria
Attahir Abubakar, Ahmadu Bello University, Nigeria
Title : Comparative efficacy of different H9N2 avian influenza virus inactivated vaccines using some commercially available adjuvants for superior control in broilers
Ayman H M El Deeb, Cairo University, Egypt
Title : Structure-based design and development of next-generation Respiratory Syncytial Virus (RSV) vaccine
Lei Chen, Yikang Biotech Suzhou Co., Ltd, China
Title : Unmasking urban immunization inequities: A cross-sectional LQAS analysis of zero-dose drivers in slum and non-slum settings of Uttar Pradesh, India
Ashish Kumar Maurya, John Snow India, India